NCT06196671View on ClinicalTrials.gov

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2026

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions
Pancreatic Cancer
Interventions
DRUG

H101

H101 15x10\^11vp intratumorally injection starts at day 1.

DRUG

Camrelizumab

Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.

All Listed Sponsors
lead

Fudan University

OTHER